Treatment regimens for patients with chronic hepatitis C

Minerva Gastroenterologica e Dietologica

Volumn 54, Issue 2, 2008, Pages 209-217

  Trapero Marugan, M ^a   Gonzalez Moreno L ^a   Chaparro Sanchez M ^a   Moreno Monteagudo, J A ^a   Borque, M J ^a   Moreno Otero, R ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Hepatitis C, chronic; Hepatitis C, therapy; Ribavirin

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; COLCHICINE; ENZYME INHIBITOR; PARACETAMOL; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN;

ANTIVIRAL THERAPY; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MENTAL DISEASE; MONOTHERAPY; PREDICTOR VARIABLE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ALGORITHMS; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; RIBAVIRIN;

EID: 44349095347     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002;36:S1-2.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26(Suppl 1):S62-5.
3. WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997;72:341-4.
4. Poynard T, Bedossa P, Opolon P. for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
5. National Institutes of Health. Consensus Development Conference Statement: Management of hepatitis C: 2002. June 10?12, 2002. Hepatology 2002;36:S3-20.
6. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002;36:S1-2.
7. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64; quiz 214-37.
8. Baillargeon MW, Sonnet PE. Lipase modified for solubility in organic solvents. Ann N Y Acad Sci 1988;542:244-9.
9. Cao SG, Zhao QY, Ding ZT, Ma L, Yu T, Wang JH et al. Chemical modification of enzyme molecules to improve their characteristics. Ann N Y Acad Sci 1990;613:460-7.
10. Chen RH, Abuchowski A, Van Es T, Palczuk NC, Davis FF. Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol). Biochim Biophys Acta 1981;660:293-8.
11. Ho DH, Brown NS, Yen A, Holmes R, Keating M, Abuchowski A et al. Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos 1986;14:349-52.
12. Knauf MJ, Bell DP, Hirtzer P, Luo ZP, Young JD, Katre NV. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 1988;263:15064-70.
13. Mast AE, Salvesen G, Brucato FH, Schnebli HP, Pizzo SV. Polyethylene glycol modification of serpins improves therapeutic potential. Biol Chem Hoppe Seyler 1990;371(Suppl):101-9.
14. Tsuji J, Hirose K, Kasahara E, Naitoh M, Yamamoto I. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. Int J Immunopharmacol 1985;7:725-30.
15. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-81.
16. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998;28:1121-7.
17. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
18. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002;123:2082-99.
19. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
20. Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E et al; North-C Group. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47:35-42.
21. Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R et al; TeraViC-4 Study Group. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-60.
22. Lindsay KL, Trepo C, Heintges T, Shiftman ML, Gordon SC, Hoefs JC et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
23. Reddy KR, Wright TL, Pockros PJ, Shiftman M, Everson G, Reindollar R et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-8.
24. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
25. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
26. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
27. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
28. Hadziyannis SJ, Sette HJr, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
29. Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 2000;39:10634-40.
30. Bonkovsky HL, Clifford BD, Smith LJ, Allan C, Banner B. High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial. Dig Dis Sci 1996;41:149-54.
31. Spadaro A, Freni MA, Ajello A, Alessi N, Barbara E, Resta ML et al. Interferon retreatment of patients with chronic hepatitis C. A long-term follow-up. Hepatogastroenterology 1999;46:3229-33.
32. Picciotto A, Campo N, Brizzolara R, Sinelli N, Torre F, Cipriani AG et al. Interferon retreatment in chronic hepatitis C: which patients to choose and what schedule to use. Eur J Gastroenterol Hepatol 1999;11:649-53.
33. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. JAMA 2001;285:193-9.
34. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Bellomo G, Belloni G et al. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study. Am J Gastroenterol 1998;93:2445-51.
35. Barbaro G, Di Lorenzo G, Belloni G, Ferrari L, Paiano A, Del Poggio P et al. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. Am J Med 1999;107:112-8.
36. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 1997;26:137S-42S.
37. Barbaro G, Barbarini G. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study. Eur J Gastroenterol Hepatol 2002;14:477-83.
38. Cornberg M, Hadem J, Herrmann E, Schuppert F, Schmidt HH, Reiser M et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol 2006;44:291-301.
39. Enriquez J, Gallego A, Torras X, Perez-Olmeda T, Diago M, Soriano V et al. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepat 2000;7:403-8.
40. Lo Iacono O, Castro A, Diago M, Moreno JA, Fernandez-Bermejo M, Vega P et al. Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy. Aliment Pharmacol Ther 2000;14:463-9.
41. Diago M, Lujan M, Valeros D, Tuset C, Marcaida G, Garcia V et al. Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon. Rev Esp Enferm Dig 2001;93:353-63.
42. Marco VD, Almasio P, Vaccaro A, Ferraro D, Parisi P, Cataldo MG et al. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. J Hepatol 2000;33:456-62.
43. Papatheodoridis GV, Cholongitas E. Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. J Viral Hepat 2004;11:287-96.
44. Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001;33:231-40.
45. San Miguel R, Guillen F, Cabases JM, Buti M. Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon. Aliment Pharmacol Ther 2002;16:1611-21.
46. Camma C, Bruno S, Schepis F, Lo Iacono O, Andreone P, Gramenzi AG et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut 2002;51:864-9.
47. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 2001;323:1151-5.
48. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML et al. HALT-C Trial Group. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Trials 2004;25:472-92.
49. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005;42:282-92.
50. Marcellin PFB, Andreone P, Brandao-Mello C, Di Bisceglie A, Rai R, Ripault MP et al. Interim safety analysis of patients enrolled in the randomized, international retreatment with Pegasys in patients not responding to prior peginterferon alfa-2b/ribavirin (RBV) combination therapy (REPEAT) study. Hepatology 2005;42:657A.
51. Sherman MYE, Deschenes M, Kradjen M, Bain V, Peltekian K, Anderson F et al. Peginterferon alfa2a (40 kD) plus ribavirin in chronic hepatitis c patients who failed previous interferon-based therapy: results of a multicentre open-label expanded access program in Canada. J Hepatol 2005;42:220.
52. Taliani GAA, Capanni M, Ferrari C, Forte P, Framarin L, Marino N et al. Pegylated interferon alfa2b plus ribavirin in the re-treatment of patients non responsive to IFN/RBV. J Hepatol 2005;42:222.
53. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
54. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33.
55. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002;37:500-6.
56. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
57. Shiffman ML. Peginterferon alfa-2a plus ribavirin for 16 or 24 weeks in patients with HCV genotype 2 or 3-Final results of the ACCELERATE trial. J Hepatol 2006;44:734A.
58. Medina J, Garcia Buey L, Moreno Monteagudo JA, Trapero Marugan M, Moreno Otero R. Therapeutic advantages of pegylation of interferon alpha in chronic hepatitis C. Rev Esp Enferm Dig 2003;95:568-74.
59. Medina J, Garcia-Buey L, Moreno-Monteagudo JA, Trapero-Mamgan M, Moreno-Otero R. Combined antiviral options for the treatment of chronic hepatitis C. Antiviral Res 2003;60:135-43.
60. Moreno-Otero R. Therapeutic modalities in hepatitis C: challenges and development. J Viral Hepat 2005;12:10-9.